Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials
Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials
复制标题
抗 EGFR 药物与标准疗法同时治疗头颈鳞状细胞癌患者的疗效和安全性：随机对照试验的系统评价和荟萃分析
DOI：
10.1002/ijc.31157
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
yawei yuan
中科院分区：
文献类型：
--
作者：
Tian Yunhong;Lin Jie;Tian Yunming;Zhang Guoqian;Zhang Weijun;yawei yuan
Agents targeting epidermal growth factor receptor (EGFR) are used to treat head and neck squamous cell carcinoma (HNSCC); however, their efficacy and safety is poorly understood. Here we evaluated the efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for HNSCC. Randomized controlled trials that evaluated addition of EGFR targeted therapy versus standard therapy alone were included. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS), overall response rate (ORR), locoregional control, and severe adverse events (SAEs, grade3). Sixteen eligible trials with 4031 patients were included. Addition of anti-EGFR regimens to standard therapy significantly improved OS of patients with HNSCC (HR50.89; 95% CI, 0.82–0.96), with a moderately elevated rate of SAEs (RR51.08; 95% CI, 1.03–1.13). Subgroup analysis indicated that the survival benefit was observed when cetuximab was administered concurrently with radiotherapy (RT) for stage III/IV patients (HR50.76; 95% CI, 0.61–0.94; p50.01), or with chemotherapy for recurrent or metastatic (R/M) HNSCC (HR50.86; 95% CI, 0.78–0.95; p50.005). Significantly increased ORR (RR51.51; 95% CI 1.05–2.18) and PFS (HR50.72; 95% CI, 0.59–0.88) were found in R/M HNSCC patients treated with anti-EGFR plus chemotherapy, while no significant improvements were found in stage III/IV patients treated with anti-EGFR plus standard therapy. In conclusion, addition of cetuximab to standard therapy may improve outcomes for R/M HNSCC patients, while causing a moderate increase in SAEs. For stage III/IV patients, anti-EGFR mAb plus RT can improve OS compared with RT alone, while replacement of chemotherapy with EGFR mAb or adding EGFR mAb to combined chemotherapy and RT did not improve outcomes.
